+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Visiongain Publishes Top 50 Pharmaceutical Wholesale & Distribution Companies 2021

04 August 2021

Visiongain has published a new report on Top 50 Pharmaceutical Wholesale & Distribution Companies 2021: Analysis of Leading Top 50 Pharmaceutical Wholesale & Distribution Companies, Forecasts by Type (Branded, Generics) AND Regional and Leading National Market Analysis AND COVID-19 Recovery Scenarios.

According to Visiongain analysis the global pharmaceutical wholesale & distribution market was valued at USD xx billion in 2020 and is expected to reach US$xx billion by 2031 while growing at a CAGR of xx% over the forecast period.

Pricing Pressure and Impact of COVID-19 on Distribution Channels
A significant focus for policymakers and the general public remains prescription price caps. Pharmaceutical rates in the United States have increased by an average of 6.2 percent over the last 10 years. After 2019, however, the rate of price hikes has eased dramatically. The pharmaceutical processing producer price index increased 3.1 percent in 2019, a decrease from a 3.7 percent rise in 2018, and well below the annual five-year rise of 5.2 percent, as recorded by the U.S. Bureau of Labour Statistics (BLS). In 2020, with just a 1.7 percent rise recorded by the BLS, producer price changes on a year-to-date basis were muted. Since most pharmaceutical prices are adjusted early in the calendar year, this is likely to indicate that for the third consecutive year, 2020 price increases will be below the trailing five-year average. In 2020, with just a 1.7 percent rise recorded by the BLS, producer price rises were muted on a year-to-date basis. Since most prescription costs are changed early in the fiscal year, this is likely to mean that price changes in 2020 will be smaller than the preceding five-year average for the third year in a row.

What is the Supply Chain Concern for Pharmaceutical Wholesale and Distribution Players?
As firms reassess their supply-chain processes and footprints to make them more flexible and resilient to disruption, COVID-19 has expanded the emphasis on risk management. Such considerations can include criteria for surplus capacity, dual procurement, and regional diversification. Make-versus-buy decisions will also be affected and will rely on how firms assess their vendors and calculate solvency risks, the amount of influence they prefer, the desire to select partners based on diversifying locations and other aspects that balance cost versus risk. In the market, there has long been an overarching feeling of unease, as central production centres are situated far from their demand. This frustration has been reinforced by the COVID-19 crisis, prompting firms to consider moving a portion of the last-mile production-supply capacity closer to the end markets. There are several questions about China and India's supply chain dependence; the number of facilities providing active pharmaceutical ingredients (API) in China has more than doubled to 13 percent of all those servicing the U.S. market since 2010 as of 2020. With nearly 25 percent of the total, the United States remains home to the most API processing plants globally.

Pharmaceutical Wholesale and Distribution to Deliver Drugs Directly to Patients
Drugs are delivered directly to the patient's door by the pharmaceutical wholesale and distribution supply chain. To deliver over the counter and general merchandise to the customer, the last mile delivery infrastructure could be deployed to generate additional revenue pockets. Distributors have full visibility between manufacturer and patient into both custody transfer and shipment details, providing them with additional insights that could be monetized. Margins may be squeezed in the short term before the demand matures and the bid is embraced by patients. The valuation of distributors is expected to increase due to the additional volume attracted by retail pharmacies. Emerging data capture and storage technologies create an opportunity for distributors to play a critical role as data intermediaries in the ecosystem.

Expanded Data Access to Fuel Pharmaceutical Wholesale and Distribution Market Through 2031
According to Visiongain analysis, offering additional extended data access & insights as a service is another possible growth driver for pharmaceutical wholesale and distributors. The companies can thus gain access to data which ranges from upstream to downstream partners, located at the center of the supply chain. With this, the distributors can leverage this position & build or acquire improved data capabilities, similar to retail pioneers, that can help them develop a deeper understanding of customers & meaningful insights to increase efficiency, and thus drive revenue growth over the forecast period, this is in-turn benefit the entire healthcare system.

Strong Distribution Network to Offer Lucrative Growth Prospects
At the root of the global health care market are pharmacy distributors. Distributors manage over 90% of the total pharmaceutical sales, bring quality, and order to a supply chain that links more than 2500 suppliers and over 500,000+ dispensing points to two extremely fragmented markets. With increasing prevalence of chronic as well as acute diseases in developed as well as emerging economies, the need of strong distribution network has increased to a drastic level. A completely balanced distribution network is the key to continuous supply of pharmaceuticals to needy. In the health care industry, distributors enhance value by providing Efficiencies for aggregation and economies of scale that reduce resources and operating costs for the broader supply chain of pharmaceuticals.

Competitive Landscape
The companies operating in the global pharmaceutical wholesale and distributors market are McKesson Corporation, Alfresa holdings, AmerisourceBergen Corp, Cardinal Health, CR Pharmaceutical Group, Kingworld Medicines Group Ltd, MEDIPAL HOLDINGS, Profarma Distribuidora de Produ, Realcan Pharmaceutical Group Co, Shanghai Pharmaceuticals Holding Co., Ltd, SINOPHARM HOLDING CO LTD, Walgreens Boots Alliance, Zhejiang Int'l Group Co. Ltd, SUZUKEN, The phoenix group pharmaceuticals, Smith Drug Company, Prodigy Health, Ohki Healthcare Holdings Co., Ltd, North Carolina Mutual Wholesale Drug, Morris & Dickson, Mawdsleys, HyGen Pharmaceuticals, Inc., Fortissa, CuraScript Special Capital Wholesale Drug Company, AAH Pharmaceuticals Ltd., Drogueria Betances, Inc., EzriRx, FCL Health Solutions, Firstline Pharma Ltd., Goodwill Pharma, H. D. Smith, Henry Schein Inc., Karo Pharma, Letco Medical, Masters Pharmaceutical, Medline Industries, Mockingbird Pharma, Mutual Drug, OTC Direct, Owens & Minor, Inc., QK Healthcare Inc., R&S Northeast LLC, RxOneShop, Safe Chain Solutions, Sigma PLC, TopRx, Value Drug Company, Premium Rx National, LLC, and Kolmar among other prominent players among other players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Cell & Gene Therapy Cold Chain Logistics Market

The global Cell and Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15.5% by 2034

19 June 2024


Cancer Immunotherapy Market

The global Cancer Immunotherapy market is projected to grow at a CAGR of 12.6% by 2034

11 June 2024


Biological Safety Testing Market

The global Biological Safety Testing market is projected to grow at a CAGR of 12.6% by 2034

11 June 2024


CAR-T Therapy Market

The global CAR-T Therapy market is projected to grow at a CAGR of 35.9% by 2034

11 June 2024